Want to join the conversation?
Belgian pharmaceutical research company $GLPG and $GILD entered into a partnership for the development and commercialization of the JAK1-selective inhibitor filgotinib for inflammatory disease indications. An upfront payment of $725MM will be given to $GLPG that comprises of a license fee of $300MM and a $425MM equity investment in $GLPG.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.